# Delian Capital

> Delian Capital is a VC fund in Beijing backing Biotechnology and Health Care. See 97 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 97
- Last investment: Jun 2026
- Lead investor: 28%
- Last updated: Aug 2026
- Website: http://bjdeliancap.com/
- Facebook: https://www.facebook.com/Delian-Capital

Delian Capital is a VC fund in Beijing focused on Biotechnology and Health Care. Founded in 2011, Delian Capital specializes in the field of tech-driven industry such as high-end manufacturing, cutting-edge technologies, and healthcare. Their investments range from robotics, Smart manufacturing Semiconductor, AI, big data, enterpriseservices, healthcare, etc.Examples of their investment portfolio: YueBoo、Hunan zhongli、Esafenet、Venus MedTech、MicuRx、Rokae、 IMI、12 Sigma Technologies.

## Contacts

5 contacts available for Delian Capital. Shizune tracks 2 team members at Delian Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/delian-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.5M–$50M |
| Series A | $1.6M–$19M |
| Series B | $9.9M–$29M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 22 | 23% |
| Health Care | 18 | 19% |
| Manufacturing | 18 | 19% |
| Medical | 12 | 12% |
| Biopharma | 10 | 10% |

91 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 30 | 31% |
| Seed | 26 | 27% |
| Series B | 12 | 12% |
| Angel | 9 | 9% |
| Series C | 7 | 7% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 70 | 72% |
| United States | 11 | 11% |
| France | 1 | 1% |
| Hong Kong | 1 | 1% |
| Singapore | 1 | 1% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Fang Hong | Managing Director | 2 | https://shizune.co/investors/profile/fang-hong |
| Quan Li | Founding Partner | 0 | https://shizune.co/investors/profile/quan-li-6ea0 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| BCI-Sonics | BCI-Sonics is an innovative medtech company developing non-invasive brain-computer interface solutions using advanced transcranial focused ultrasound (tFUS) technology. The company builds a next-generation therapeutic platform enabling precise neuromodulation to treat central nervous system disorders. BCI-Sonics develops low-intensity focusedultrasound technology that non-invasively stimulates deep brain regions with high precision. They combine ultrasound engineering and neuroscience to interface safely and effectively with the human brain without surgery. The company is creating an AI ultrasound brain-computer interface platform for therapeutic neuromodulation applications. | $14.8M | Angel | Jun 08, 2026 |  |
| Gnosis Healthineer | Gnosis Healthineer provides medical devices to hospitals such as Clinical EEG AI Model. It builds an EEG data center for second- and third-level general hospitals to solve the problem of insufficient EEG data storage. The hardware construction of the data center includes: PB-level storage and servers, and high-performance computing equipment. | $14.8M | Series A | Jun 05, 2026 |  |
| Genrobot.ai | Genrobot.ai develops AI-powered robots for automation, data analysis, and intelligent task management across industries. |  | Seed | Jun 01, 2026 |  |
| Junhe Atom | Junhe Atom is a company that focuses on Small modular nuclear reactors. |  | Angel | May 22, 2026 |  |
| MingShi Brain-Computer Interaction | Mindtrix (明视脑机) develops brain–computer‑interface technology focused on reconstructing visual information and neural signals from the brain, primarily for visual‑reconstruction and implantable‑BCI applications. It conducts research and builds systems to decode brain‑wave patterns and translate them into machine‑interpretable outputs, aiming atadvanced neurotechnology and human–machine interfaces. The company also works on underlying hardware and software platforms that support high‑precision neural data acquisition, processing, and real‑time feedback loops. | $21.8M | Angel | Apr 02, 2026 |  |
| Rigerna | Rigerna develops unique small nucleic acid medicines and innovative nucleic acid therapies for nonliver tissues. | $29M | Seed | Mar 20, 2026 |  |
| Neowise | XinjingZhiyuan is an immune cell therapy company focusing on solid tumors. | $28.7M | Series B | Jan 26, 2026 |  |
| Neowise | XinjingZhiyuan is an immune cell therapy company focusing on solid tumors. | $28.7M | Series B | Jan 26, 2026 |  |
| Zendure | Zendure specialized in research, development, and sale of residential energy storage and energy management systems. It focuses on the development of fields including industrial design, structure, software, and hardware. |  | Series B | Dec 31, 2025 |  |
| Lingke Medical | Lingke Medical is a company specializing in intelligent temperature-controlled therapy technology, dedicated to developing innovative medical solutions that integrate advanced sensing, precise thermal regulation, and smart control systems to improve treatment effectiveness, patient comfort, and clinical outcomes across a range of healthcareapplications. |  | Series A | Dec 15, 2025 |  |

10 of 97 investments shown.

## Co-investors
- [Longpan Investment](https://shizune.co/investors/profile/longpan-investment) — VC Fund, 4 deals together
- [AU21 Capital](https://shizune.co/investors/profile/au21-capital) — VC Fund, 3 deals together
- [CICC](https://shizune.co/investors/profile/cicc) — VC Fund, 3 deals together
- [Co-Stone Venture Capital](https://shizune.co/investors/profile/co-stone-capital) — VC Fund, 3 deals together
- [Digital Finance Group (DFG)](https://shizune.co/investors/profile/digital-finance-group) — VC Fund, 3 deals together
- [Legend Star](https://shizune.co/investors/profile/legendstar) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Health Care VC Funds in China](https://shizune.co/investors/health-care-vc-funds-china)
- [Biotech Investors in China](https://shizune.co/investors/biotech-investors-china)
- [Biotech VC Funds in China](https://shizune.co/investors/biotech-vc-funds-china)
- [Biotech Investors in Asia](https://shizune.co/investors/biotech-investors-asia)
- [Biotech VC Funds in Asia](https://shizune.co/investors/biotech-vc-funds-asia)
- [Health Care Investors in China](https://shizune.co/investors/health-care-investors-china)

## FAQ

### What does Delian Capital invest in?

Delian Capital invests primarily in Biotechnology, Health Care and Manufacturing startups, most often at Series A and Seed stage. Most of the 97 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Delian Capital's check size?

Delian Capital typically joins rounds of $1.5M–$50M at Seed, $1.6M–$19M at Series A and $9.9M–$29M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Delian Capital participates in.

### How do I contact Delian Capital?

Public channels for Delian Capital include the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Delian Capital?

The team at Delian Capital includes Fang Hong (Managing Director) and Quan Li (Founding Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co